Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Virax Biolabs Group Ltd. Class A ( (VRAX) ) is now available.
On December 3, 2025, Virax Biolabs Group Limited announced a $5 million private placement agreement with an accredited investor, involving the sale of 12,500,000 ordinary shares and preferred investment options. The private placement, which closed on December 4, 2025, aims to use the net proceeds for working capital and general corporate purposes. This strategic move is expected to bolster Virax’s financial position and support its ongoing research and development efforts in immunology and diagnostics, potentially enhancing its market positioning and offering value to stakeholders.
The most recent analyst rating on (VRAX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases. The company is developing T cell-based test technologies aimed at providing an immunology profiling platform, which can be particularly effective in diagnosing and treating post-acute infection syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
Average Trading Volume: 4,926,786
Technical Sentiment Signal: Sell
Current Market Cap: $1.71M
For detailed information about VRAX stock, go to TipRanks’ Stock Analysis page.